iac melbourne 21 july 2014 n.
Skip this Video
Loading SlideShow in 5 Seconds..
IAC, Melbourne 21 July, 2014 PowerPoint Presentation
Download Presentation
IAC, Melbourne 21 July, 2014

Loading in 2 Seconds...

play fullscreen
1 / 18

IAC, Melbourne 21 July, 2014 - PowerPoint PPT Presentation

  • Uploaded on

Overcoming Patent barriers to hepatitis C treatment The Hepatitis C Treatment Revolution Expanding Access to HIV Co-Infected and Beyond UNITAID, MSF, WHO. IAC, Melbourne 21 July, 2014. Drugs of Interest - Hepatitis C. Sofosbuvir Will likely be backbone of HCV all-oral pan-genotypic regimens

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'IAC, Melbourne 21 July, 2014' - cyrus-walter

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
iac melbourne 21 july 2014

Overcoming Patent barriers to hepatitis C treatment The Hepatitis C Treatment Revolution Expanding Access to HIV Co-Infected and BeyondUNITAID, MSF, WHO

IAC, Melbourne 21 July, 2014

drugs of interest hepatitis c
Drugs of Interest - Hepatitis C


Will likely be backbone of HCV all-oral pan-genotypic regimens

MSF planning to use in our treatment programs


Significantly strengthens sofosbuvir regimens and likely reduces duration

Potential component (e.g. with sofosbuvir) of pan-genotypic all oral regimen

Very good activity in genotype 3


Potential for pan-genotypic all-oral regimen (e.g. with sofosbuvir) – but need to

evaluate further studies that are on-going

potential for FDC with sofosbuvir for GT 1 and 4 – data already available

GS 5816

Very good pan-genotypic potential, but need to see results of on-going studies

local patents linked to local prices
Local Patents linked to Local Prices


No patent

One supplier

Multiple producers

No competition


High prices of

imported medicines

Access to low cost

generic medicines

the grounds for opposing patent applications on sofosbuvir

24 Nov 2013: opposition to the patent application on the pro-drug

The opposition, filed at the Kolkata Patent Office by I-MAK targets Gilead’s patent application 3658/KOLNP/2009 (WO2008/121634).

19 March 2014: opposition to the patent application on the base compound

The opposition, filed at the Delhi Patent Office by I-MAK and the Delhi Network of Positive People (DNP+) targets Gilead’s patent application 6087/DELNP/2005

(WO 2005/003147).

Lack of novelty - The base compound has been disclosed in variousearlier

patents, whichalreadyreveal the free base compound that is used

in sofosbuvir

The complete patent opposition documents are available.

the treatment regime msf doctors dream of
The treatment regime MSF doctors dream of!

Which DAAs

  • Sofosbuvir + Daclastavir (NUC + NS5a)
  • pan-genotypic
  • Better treatment outcomes for patients with advanced liver disease

In what form?

  • Co-blister
  • Fixed dose combination
  • Pediatric formulation
the barriers
The barriers
  • Clinical trials - Gilead won’t cooperate with BMS
  • Then we wait for sofosbuvir and daclastavir to be registered separately
  • Generic production of sofosbuvir in the pipeline
  • Generic production of daclastavir? Dialogue with generic producers needed to stimulate interest.
  • Likely scenario – sofosbuvir will not be patented in India. Daclastavir (at least compound) could be patented…(impact of new patent regime in India)
  • Challenge – how do you ensure generic supply of sofosbuvir and daclastavir together for medical projects
what trips flexibilities
What TRIPS flexibilities?
  • Finding the patent applications (WHO and I-MAK)
  • Filing pre-grant oppositions (starting with India)
  • If and when a patent is granted on daclastavir, use of bolar provision will protect generic companies from infringement suits for developing, registering and pre-qualifying (BE & stability studies) of generic formulations of daclastavir (section 107A of Indian law)
  • Compulsory licensing for daclastavir (building a dossier for Indian government and placing an order)
  • Can the drug be produced in an LDC (using the LDC extension for opening up generic supply of new DAAs patented in India

What are governments doing about this?

marketing authorization registration status in india
Marketing authorization/Registration status in India
  • Registration in developed countries - On the two drugs (sofosbuvir & simeprevir) despite having completed phase II trials (phase 3 data is awaited), were considered for accelerated approval by the USFDA & EMA as they appear to offer significant advantages over available therapies. Another drug daclastavir is also likely to receive approval in August 2014.
  • Local registration - For new oral drugs to be available in the India market, first companies (originator or Indian generic company) have to submit registration dossiers to the Indian Drug Regulatory Authority (Drug Controller General of India). This is yet to happen and therefore the drugs are not available locally. In India.
  • Gilead is yet to apply for registration of sofosbuvir. As per the Indian law – the Drugs & Cosmetic Act - it is doing a local trial covering 100 patients. Therefore registration of sofosbuvir in India is unlikely in 2014. Maybe 2015 if the Indian FDA does not delay.
  • Gilead will submit its dossier only after completion of the local trial. For other drugs like daclastavir and simeprevir we are unaware if the companies have initiated any steps to register these drugs or conducting clinical trials in India. Generic companies too could initiate the registration process but till now no company has stepped forward to do so.

More and more patients failing current treatment regimen (Peg inf+Ribavirin) are being prescribed new DAAs (Sofosbuvir) and asked to import from US if possible (cost 26,000 canadian $ for 28 tablets)

  • Cases of denial of treatment starting to emerge (human rights issues).
compassionate use
Compassionate use
  • What is the option for patients who need new HCV drugs immediately:Compassionate use allows the possibility to use (outside of clinical trials) by a clinician a new drug yet unregistered in India for patients suffering from a life threatening disease and for whom conventional therapies have failed.
  • In other words, when no other treatments are available to a seriously ill patient, clinicians can sometimes use a new, unapproved drug. Such provisions are mainly used by Indian clinicians for diseases like cancer to provide access to treatments that are still under development and that have not yet received marketing authorization in India.
compassionate use1
Compassionate use
  • For patients who have either failed or cannot tolerate treatments based on interferon injections and are in urgent need of treatment there are legal safeguards in the Drugs & Cosmetic Act that allow access to new drugs which are yet to be registered in India.
  • Please note that Indian law does not directly recognize the concept of compassionate use but clearly allows for use of new unregistered drugs imported under a special license in small quantities for life threatening diseases or such disease requiring therapies for unmet medical needs.
compassionate use2
Compassionate use

There are three steps to this process:

  • Step 1
  • Applying to the company for compassionate use – does the company accepts the request for compassionate use for this we must identify whether the company (for sofosbuvir it is Gilead, for simeprevir its is Janssen and for daclastavir is it BMS) have a Compassionate Use program open to process requests.
  • Gilead’s criteria for CU –only those who have had liver transplant are eligible
  • Janssen setting up a compassionate use programme for Asia
  • Daclastavir - BMS - ?
compassionate use3
Compassionate use
  • Step 2
  • Once the company responds affirmatively then the patient must apply to the Drug Controller General of India for permission –
  • The new unregistered drug can be imported under Rule 36 (import of drugs for personal use), by filing and submiting form 12A (Application for the issue of a permit to import small quantities of drugs for personal use). Form 12A is to be filled by the patient (attaching the prescription of the doctor.)
  • the DCGI grants permission under 12B (Permit for the import small quantities of drugs for personal use.
  • Apply for waiver of custom tax to MoH
  • If granted this will be sufficient to legally import the drugs.
  • Step 3
  • Once the drug has been dispatched by the company, the import shipment (consignment of the drug) has to be custom cleared and picked up from the airport with the original Import Permit (12B Form) and other necessary documents.